Lung cancer tumor immune microenvironment: analyzing immune escape mechanisms and exploring emerging therapeutic...

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Lung cancer remains a leading global malignancy with persistent challenges in treatment efficacy, including high recurrence rates, drug resistance, and significant toxic side effects.
• While conventional therapies (chemotherapy, radiotherapy, targeted therapy) have improved survival, and immune checkpoint inhibitors (ICIs) targeting programmed cell death-1/programmed cell death ligand 1 have transformed treatment paradigms, significant hurdles persist.
• A substantial subset of patients exhibit poor response rates or develop resistance to ICIs, underscoring the critical role of tumor immune escape.

Purpose of the Study:

• To systematically review the multifaceted mechanisms of immune escape within the lung cancer immunological microenvironment.
• To identify and summarize emerging therapeutic targets and promising clinical trials aimed at overcoming immune evasion in lung cancer.
• To establish a robust theoretical framework for advancing research on lung cancer immune escape, developing novel immunotherapeutic strategies, and enabling personalized treatment approaches.

Main Methods:

• Systematic literature review focusing on the immunological microenvironment of lung cancer.
• Analysis of mechanisms contributing to tumor immune escape, including metabolic reprogramming, immune checkpoint molecule overexpression, and antigen presentation abnormalities.
• Compilation of data on novel therapeutic targets and ongoing clinical trials in lung cancer immunotherapy.

Main Results:

• Key mechanisms of immune escape in lung cancer include metabolic reprogramming, overexpression of immune checkpoint molecules (e.g., PD-1/PD-L1), and defects in antigen presentation.
• These escape mechanisms contribute to the limited efficacy and resistance observed with current immunotherapies in a significant portion of lung cancer patients.
• Emerging therapeutic strategies and ongoing clinical trials show promise in targeting these escape pathways.

Conclusions:

• Understanding the intricate mechanisms of immune escape is crucial for improving lung cancer treatment outcomes.
• Novel therapeutic targets and personalized strategies are essential to overcome resistance and enhance response rates to immunotherapy.
• This review provides a foundation for future research and clinical development in lung cancer immunotherapy.